\
&
Contact us
Starts in 1 week from now
LocationHybrid (Brussels and online)
The event showcases EU-funded projects and synergies from HaDEA’s portfolio focusing on digital technology, industry, space and health. Attendees will have the opportunity to connect with project leaders, innovators, and policymakers to explore collaborations that enhance Europe’s competitiveness and preparedness.
The HaDEA Showcase Event features high-level panel debates, keynotes, and project spotlights focusing on breakthrough EU-funded innovations. Participants can engage in networking opportunities with experts, industry actors, and EU representatives. The event is hybrid, allowing attendance in person at the Charlemagne Conference Centre in Brussels (registration required) or online without registration. Flanders-based researchers and innovators may find valuable insights and contacts relevant to funding opportunities under Horizon Europe and other EU initiatives.
Target group: researchers, entrepreneurs, policymakers
For more information and the possibility to register for in-person attendance at the Charlemagne Conference Centre please visit the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.